Pfizer 8-K
Guidance reaffirmed
CFO transition announced; all FY2026 guidance reaffirmed.
Filed 2026-06-18 13:17 ET
- 7.01 Regulation FD Disclosure
Summary
FY2026 guidance reaffirmation. Following its CFO transition announcement, Pfizer reaffirmed all components of its full-year 2026 guidance.
Guidance
| Metric | Period | Guidance | Prior | Direction |
|---|---|---|---|---|
| Revenue | FY2026 | $59.5B-$62.5B | $59.5B-$62.5B | reaffirmed |
| Adjusted diluted EPS, non-GAAP | FY2026 | $2.80-$3.00 | $2.80-$3.00 | reaffirmed |
Investor Takeaways
- FY2026 results vs the reaffirmed revenue and adjusted diluted EPS ranges.
The summary is written by an AI model reading the filing.
Model 005 · prompt 01d34d48e3